Dapagliflozin in Patients with Chronic Kidney Disease

Abstract

Among patients with chronic kidney disease, regardless of the presence or absence of diabetes, the risk of a composite of a sustained decline in the estimated GFR of at least 50%, end-stage kidney disease, or death from renal or cardiovascular causes was significantly lower with dapagliflozin than with placebo. (Funded by AstraZeneca; DAPA-CKD ClinicalTrials.gov number, NCT03036150.).

Keywords

Affiliated Institutions

• Nanfang Hospital CN
• Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán MX
• Southwestern Medical Center
• University of Utah US
• AstraZeneca (Sweden) SE
• Stanford University US
• Friedrich-Alexander-Universität Erlangen-Nürnberg DE
• University College London GB
• Southern Medical University CN
• University of Groningen NL
• The University of Texas Southwestern Medical Center US
• University Medical Center Groningen NL
• University of Copenhagen DK

Related Publications